Core Insights - Alcon is showcasing innovative technologies and presenting new study findings at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen from September 12-15, 2025 [1][2] Product Innovations - Alcon is highlighting its latest innovations available in Europe, including the UNITY Vitreoretinal Cataract System (VCS), Clareon Vivity intraocular lens (IOL), and Voyager Direct Selective Laser Trabeculoplasty (DSLT) [2][5] - The Clareon Vivity IOL is noted as the most implanted extended depth of focus (EDOF) IOL worldwide, designed to deliver presbyopia correction [5] - Voyager DSLT is the first and only device of its kind, aimed at simplifying selective laser trabeculoplasty and enhancing patient experience [5] Clinical Evidence - More than 40 studies will be presented at the conference, demonstrating the benefits of Alcon technologies across various procedures including cataract, refractive, vitreoretinal, and glaucoma [6] - New data on Vivity IOLs indicate positive outcomes and patient satisfaction, particularly in special populations with co-morbidities [7] - Studies show reduced breakthrough pain medication use and less patient discomfort when performing cataract surgery at more physiologic intraocular pressure (IOP) [4][7] Symposium and Activities - Alcon will host a symposium focused on optimizing cataract surgery with near physiologic IOP, featuring expert faculty [8] - Additional symposium sessions and live surgery presentations will showcase Alcon's advanced technologies and their applications [10] Company Overview - Alcon is a global leader in eye care, with revenues of $9.8 billion and a net income of $1.5 billion in 2024 [18][23] - The company has a broad portfolio of products that enhance sight and improve lives, impacting over 260 million people annually [15]